dexamethasone
Phase 2- Indications
- Deep Vein Thrombosis, Post-thrombotic syndrome
Company intelligence / Profile preview
Mercator MedSystems develops catheter-based micro-infusion technologies that enable site-specific, non-systemic drug, gene, or cell delivery directly through blood vessel walls into deep tissues. Their Bullfrog Micro-infusion Device has shown promise in early clinical trials to reduce post-thrombotic syndrome after DVT by delivering dexamethasone locally. The company’s TANGO Phase II trial demonstrated improved outcomes after below-knee arterial revascularization. Several of their devices are FDA cleared and CE marked.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mercator MedSystems.